Prelude Therapeutics Stock Market Outlook
| PRLD Stock | USD 2.24 0.15 7.18% |
About 75 percent of all Prelude Therapeutics' shareholders are curious in acquiring. The analysis of the overall investor sentiment regarding Prelude Therapeutics suggests that quite a large number of traders are confidant. The current market sentiment, together with Prelude Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prelude Therapeutics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 75
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Prelude Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Prelude Therapeutics.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentAcquiring |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Prelude Therapeutics is 'Sell'. Macroaxis provides Prelude Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PRLD positions.
Execute Prelude Therapeutics Advice
The Prelude recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Prelude Therapeutics. Macroaxis does not own or have any residual interests in Prelude Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Prelude Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Fair | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Strong | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Prelude Therapeutics has a Mean Deviation of 6.13, Semi Deviation of 6.74, Standard Deviation of 8.07, Variance of 65.11, Downside Variance of 58.75 and Semi Variance of 45.4We provide trade recommendations to complement the recent expert consensus on Prelude Therapeutics. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Prelude Therapeutics is not overpriced, please check all Prelude Therapeutics fundamentals, including its number of shares shorted, cash per share, price to earnings to growth, as well as the relationship between the gross profit and book value per share . Please also confirm Prelude Therapeutics price to book to check out your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Prelude Therapeutics Trading Alerts and Improvement Suggestions
| Prelude Therapeutics is way too risky over 90 days horizon | |
| Prelude Therapeutics appears to be risky and price may revert if volatility continues | |
| Prelude Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 10.5 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Prelude Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 55.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Prelude Therapeutics Trading Down 0.9 percent Heres What Happened |
Prelude Therapeutics Returns Distribution Density
The distribution of Prelude Therapeutics' historical returns is an attempt to chart the uncertainty of Prelude Therapeutics' future price movements. The chart of the probability distribution of Prelude Therapeutics daily returns describes the distribution of returns around its average expected value. We use Prelude Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Prelude Therapeutics returns is essential to provide solid investment analysis for Prelude Therapeutics.
| Mean Return | 1.28 | Value At Risk | -12.9 | Potential Upside | 13.57 | Standard Deviation | 8.07 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Prelude Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Prelude Stock Institutional Investors
| Shares | Royal Bank Of Canada | 2025-06-30 | 2.8 K |
Prelude Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | (263.8M) | 81.7M | (41.0M) | 90.2M | 103.7M | 108.9M | |
| Change In Cash | (182.4M) | (1.2M) | (5.3M) | (12.8M) | (11.5M) | (11.0M) | |
| Free Cash Flow | (85.9M) | (86.7M) | (110.6M) | (103.7M) | (93.3M) | (98.0M) | |
| Depreciation | 915K | 1.3M | 1.2M | 1.8M | 2.0M | 2.1M | |
| Other Non Cash Items | 2.7M | 4.3M | (1.5M) | (3.0M) | (2.7M) | (2.6M) | |
| Capital Expenditures | 2.3M | 3.0M | 3.5M | 764K | 878.6K | 834.7K | |
| Net Income | (111.7M) | (115.4M) | (121.8M) | (127.2M) | (114.5M) | (120.2M) | |
| End Period Cash Flow | 35.9M | 34.6M | 29.3M | 16.5M | 14.9M | 14.1M | |
| Change To Netincome | 856K | 5.6M | 23.6M | 29.5M | 33.9M | 35.6M |
Prelude Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Prelude Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Prelude Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Prelude stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.25 | |
β | Beta against Dow Jones | 0.29 | |
σ | Overall volatility | 8.29 | |
Ir | Information ratio | 0.15 |
Prelude Therapeutics Volatility Alert
Prelude Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Prelude Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Prelude Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Prelude Therapeutics Fundamentals Vs Peers
Comparing Prelude Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Prelude Therapeutics' direct or indirect competition across all of the common fundamentals between Prelude Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Prelude Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Prelude Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Prelude Therapeutics to competition |
| Fundamentals | Prelude Therapeutics | Peer Average |
| Return On Equity | -1.04 | -0.31 |
| Return On Asset | -0.52 | -0.14 |
| Operating Margin | (3.14) % | (5.51) % |
| Current Valuation | 93.97 M | 16.62 B |
| Shares Outstanding | 43.77 M | 571.82 M |
| Shares Owned By Insiders | 9.93 % | 10.09 % |
| Shares Owned By Institutions | 55.45 % | 39.21 % |
| Number Of Shares Shorted | 2.07 M | 4.71 M |
| Price To Book | 2.24 X | 9.51 X |
| Price To Sales | 12.51 X | 11.42 X |
| Revenue | 7 M | 9.43 B |
| Gross Profit | 10.5 M | 27.38 B |
| EBITDA | (137.94 M) | 3.9 B |
| Net Income | (127.17 M) | 570.98 M |
| Cash And Equivalents | 246.3 M | 2.7 B |
| Cash Per Share | 5.19 X | 5.01 X |
| Total Debt | 18.02 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 15.73 X | 2.16 X |
| Book Value Per Share | 0.77 X | 1.93 K |
| Cash Flow From Operations | (102.89 M) | 971.22 M |
| Short Ratio | 4.32 X | 4.00 X |
| Earnings Per Share | (1.47) X | 3.12 X |
| Price To Earnings To Growth | (0.09) X | 4.89 X |
| Target Price | 4.0 | |
| Number Of Employees | 131 | 18.84 K |
| Beta | 0.87 | -0.15 |
| Market Capitalization | 131.39 M | 19.03 B |
| Total Asset | 175.51 M | 29.47 B |
| Retained Earnings | (583.56 M) | 9.33 B |
| Working Capital | 110.25 M | 1.48 B |
| Net Asset | 175.51 M |
Note: Acquisition by Friedman Paul A of 23500 shares of Prelude Therapeutics at 5.56 subject to Rule 16b-3 [view details]
Prelude Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Prelude . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 30704.7 | |||
| Daily Balance Of Power | 0.5172 | |||
| Rate Of Daily Change | 1.07 | |||
| Day Median Price | 2.15 | |||
| Day Typical Price | 2.18 | |||
| Price Action Indicator | 0.16 | |||
| Period Momentum Indicator | 0.15 |
About Prelude Therapeutics Buy or Sell Advice
When is the right time to buy or sell Prelude Therapeutics? Buying financial instruments such as Prelude Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Prelude Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Prelude Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Biotechnology sector continue expanding? Could Prelude diversify its offerings? Factors like these will boost the valuation of Prelude Therapeutics. Anticipated expansion of Prelude directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Prelude Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Prelude Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prelude Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Prelude Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.